Literature DB >> 2523227

The renal effects of atrial natriuretic peptide in man are not attenuated by (+)-sulpiride.

S Freestone1, T M MacDonald, R F Jeffrey, J Brown, M R Lee.   

Abstract

1. Human alpha atrial natriuretic peptide (ANP) was infused intravenously for 1 h in eight healthy salt-replete men on two occasions, with and without pretreatment with (+)-sulpiride. 2. ANP increased sodium excretion and urine flow rate but did not alter blood pressure or plasma renin activity. 3. (+)-sulpiride had no significant effect on baseline creatinine clearance, sodium excretion or urine flow rate and did not alter the increases in these parameters with ANP. 4. It is unlikely that the renal effects of ANP are mediated by dopamine DA1-receptors in man.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523227      PMCID: PMC1379699          DOI: 10.1111/j.1365-2125.1989.tb05329.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  THE DISTRIBUTION OF DOPAMINE AND DOPA IN VARIOUS ANIMALS AND A METHOD FOR THEIR DETERMINATION IN DIVERSE BIOLOGICAL MATERIAL.

Authors:  A H ANTON; D F SAYRE
Journal:  J Pharmacol Exp Ther       Date:  1964-09       Impact factor: 4.030

2.  Urinary dopamine in man and rat: effects of inorganic salts on dopamine excretion.

Authors:  S G Ball; N S Oats; M R Lee
Journal:  Clin Sci Mol Med       Date:  1978-08

3.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

4.  Renal, haemodynamic, and hormonal effects of human alpha atrial natriuretic peptide in healthy volunteers.

Authors:  A M Richards; M G Nicholls; H Ikram; M W Webster; T G Yandle; E A Espiner
Journal:  Lancet       Date:  1985-03-09       Impact factor: 79.321

5.  Stereoselectivity of S- and R-sulpiride for pre- and postsynaptic dopamine receptors in the canine kidney.

Authors:  A S Bass; N W Robie
Journal:  J Pharmacol Exp Ther       Date:  1984-04       Impact factor: 4.030

6.  Separation of peripheral dopamine receptors by a selective DA1 antagonist, SCH 23390.

Authors:  L I Goldberg; D Glock; J D Kohli; A Barnett
Journal:  Hypertension       Date:  1984 Mar-Apr       Impact factor: 10.190

7.  Direct radioimmunoassay of atrial natriuretic factor.

Authors:  J Gutkowska; G Thibault; P Januszewicz; M Cantin; J Genest
Journal:  Biochem Biophys Res Commun       Date:  1984-07-31       Impact factor: 3.575

8.  Atrial natriuretic peptide: an endogenous factor enhancing sodium excretion in man.

Authors:  J Anderson; A Struthers; N Christofides; S Bloom
Journal:  Clin Sci (Lond)       Date:  1986-04       Impact factor: 6.124

9.  Plasma levels and cardiovascular, endocrine, and excretory effects of atrial natriuretic peptide during different sodium intakes in man.

Authors:  P Weidmann; B Hellmueller; D E Uehlinger; R E Lang; M P Gnaedinger; L Hasler; S Shaw; C Bachmann
Journal:  J Clin Endocrinol Metab       Date:  1986-05       Impact factor: 5.958

10.  Dopamine receptor antagonists inhibit the natriuretic response to atrial natriuretic factor (ANF).

Authors:  M Marin-Grez; J P Briggs; G Schubert; J Schnermann
Journal:  Life Sci       Date:  1985-06-03       Impact factor: 5.037

View more
  5 in total

1.  DOPA decarboxylase inhibition does not influence the diuretic and natriuretic response to exogenous alpha-atrial natriuretic peptide in man.

Authors:  S Kageyama; J Brown; R Causon; M O'Flynn; V Aber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Effects of felodipine on atrial natriuretic peptide in hypertensive non-insulin dependent diabetes mellitus.

Authors:  R F Jeffrey; S Capewell; J Brown; A Collier; C Hajducka; M R Lee
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

3.  Renal effects of atrial natriuretic peptide during dopa-decarboxylase inhibition in patients with essential hypertension.

Authors:  C Fronzaroli; G La Villa; G Strazzulla; M Mannelli; F Franchi
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Atrial natriuretic peptide in stable and decompensated chronic obstructive pulmonary disease.

Authors:  K Skwarski; M Lee; L Turnbull; W MacNee
Journal:  Thorax       Date:  1993-07       Impact factor: 9.139

5.  Effect of alpha-human atrial natriuretic peptide on the synthesis of dopamine in the rat kidney.

Authors:  P Soares-da-Silva; M H Fernandes
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.